AKT1 and prostate carcinoma: In prostate cancer, targeting PI3K/AKT signalling by combining PI3Kβ or AKT inhibitors with inhibitors of androgen signalling increases anti-tumour effects in PTEN null tumour cell lines and tumour models due to reciprocal crosstalk between these two pathways [14, 19, 20].